FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055099239> ?p ?o ?g. }

• W2055099239 endingPage "5403" @default.
• W2055099239 startingPage "5403" @default.
• W2055099239 abstract "To investigate the effect and mechanism of action of erlotinib, an epidermal growth factor receptor (EGFR) small molecule tyrosine kinase inhibitor (TKI), in the human pancreatic cancer cell line BxPC-3 both in vitro and in vivo.In vitro, human pancreatic cancer cell line BxPC-3 was exposed to varying concentrations of erlotinib, and its effects on proliferation, cell cycle distribution, apoptosis and the expression of pro- and antiapoptotic factors such as bcl-2, bcl-xl, bax and bak, and the expression of vascular endothelial cell growth factor (VEGF) were measured with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, flow cytometric analysis, terminal deoxynucleotidyl transferase-mediated nick end labeling assay (TUNEL), and reverse transcription-polymerase chain reaction (RT-PCR). Potential effect of erlotinib on angiogenesis was examined by tube formation assay. Tumor growth suppression was observed in xenografted nude mice with pancreatic cancer in vivo. Immunohistochemical (IHC) staining for EGFR and factor VIII-related antigen was undertaken to detect the microvessel density and VEGF expression in tumor tissue in xenograft nude mice.Erlotinib, as a single agent, repressed BxPC-3 cell growth in a dose-dependent manner, triggered G(1) arrest and induced cell apoptosis, and suppressed capillary formation of endothelium in vitro. Expressions of VEGF were significantly down-regulated at a high concentration of 200 mumol/L, however, the expressions of bcl-2 and bcl-xl were decreased at 50 mumol/L. In vivo, Erlotinib-treated mice demonstrated a reduced tumor volume, weight and microvessel density as compared to the control. IHC staining showed decreased expression of EGFR and RT-PCR had lower VEGF expression in treated mice.The in vitro and in vivo findings provide evidence that BxPC-3 cells are inhibited with erlotinib treatment. Inhibition of EGFR may be a promising adjuvant chemotherapy strategy in pancreatic cancer treatment." @default.
• W2055099239 created "2016-06-24" @default.
• W2055099239 creator A5005659845 @default.
• W2055099239 creator A5035396509 @default.
• W2055099239 creator A5054579907 @default.
• W2055099239 creator A5080918862 @default.
• W2055099239 creator A5082863681 @default.
• W2055099239 date "2008-01-01" @default.
• W2055099239 modified "2023-10-16" @default.
• W2055099239 title "Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line" @default.
• W2055099239 cites W1736865258 @default.
• W2055099239 cites W1913061990 @default.
• W2055099239 cites W1965402114 @default.
• W2055099239 cites W1976701900 @default.
• W2055099239 cites W1981477203 @default.
• W2055099239 cites W1984361743 @default.
• W2055099239 cites W1989019868 @default.
• W2055099239 cites W1989865575 @default.
• W2055099239 cites W1991028764 @default.
• W2055099239 cites W2014133561 @default.
• W2055099239 cites W2032573089 @default.
• W2055099239 cites W2034642746 @default.
• W2055099239 cites W2065093995 @default.
• W2055099239 cites W2103134643 @default.
• W2055099239 cites W2106585301 @default.
• W2055099239 cites W2111039168 @default.
• W2055099239 cites W2116864064 @default.
• W2055099239 cites W2118520585 @default.
• W2055099239 cites W2137600224 @default.
• W2055099239 cites W2142564546 @default.
• W2055099239 cites W2152643817 @default.
• W2055099239 cites W2152697120 @default.
• W2055099239 cites W2153335790 @default.
• W2055099239 cites W2158134441 @default.
• W2055099239 cites W2161142009 @default.
• W2055099239 cites W2161235207 @default.
• W2055099239 cites W2284392711 @default.
• W2055099239 cites W2340759588 @default.
• W2055099239 cites W4247785462 @default.
• W2055099239 doi "https://doi.org/10.3748/wjg.14.5403" @default.
• W2055099239 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2744159" @default.
• W2055099239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18803351" @default.
• W2055099239 hasPublicationYear "2008" @default.
• W2055099239 type Work @default.
• W2055099239 sameAs 2055099239 @default.
• W2055099239 citedByCount "14" @default.
• W2055099239 countsByYear W20550992392012 @default.
• W2055099239 countsByYear W20550992392014 @default.
• W2055099239 countsByYear W20550992392015 @default.
• W2055099239 countsByYear W20550992392016 @default.
• W2055099239 countsByYear W20550992392017 @default.
• W2055099239 countsByYear W20550992392020 @default.
• W2055099239 countsByYear W20550992392023 @default.
• W2055099239 crossrefType "journal-article" @default.
• W2055099239 hasAuthorship W2055099239A5005659845 @default.
• W2055099239 hasAuthorship W2055099239A5035396509 @default.
• W2055099239 hasAuthorship W2055099239A5054579907 @default.
• W2055099239 hasAuthorship W2055099239A5080918862 @default.
• W2055099239 hasAuthorship W2055099239A5082863681 @default.
• W2055099239 hasBestOaLocation W20550992391 @default.
• W2055099239 hasConcept C121608353 @default.
• W2055099239 hasConcept C126322002 @default.
• W2055099239 hasConcept C153911025 @default.
• W2055099239 hasConcept C154113507 @default.
• W2055099239 hasConcept C167734588 @default.
• W2055099239 hasConcept C185592680 @default.
• W2055099239 hasConcept C190283241 @default.
• W2055099239 hasConcept C196795494 @default.
• W2055099239 hasConcept C2776362946 @default.
• W2055099239 hasConcept C2777025900 @default.
• W2055099239 hasConcept C2778087573 @default.
• W2055099239 hasConcept C2779438470 @default.
• W2055099239 hasConcept C2780210213 @default.
• W2055099239 hasConcept C2780394083 @default.
• W2055099239 hasConcept C2909325608 @default.
• W2055099239 hasConcept C502942594 @default.
• W2055099239 hasConcept C54355233 @default.
• W2055099239 hasConcept C55493867 @default.
• W2055099239 hasConcept C62112901 @default.
• W2055099239 hasConcept C71924100 @default.
• W2055099239 hasConcept C81885089 @default.
• W2055099239 hasConcept C86803240 @default.
• W2055099239 hasConceptScore W2055099239C121608353 @default.
• W2055099239 hasConceptScore W2055099239C126322002 @default.
• W2055099239 hasConceptScore W2055099239C153911025 @default.
• W2055099239 hasConceptScore W2055099239C154113507 @default.
• W2055099239 hasConceptScore W2055099239C167734588 @default.
• W2055099239 hasConceptScore W2055099239C185592680 @default.
• W2055099239 hasConceptScore W2055099239C190283241 @default.
• W2055099239 hasConceptScore W2055099239C196795494 @default.
• W2055099239 hasConceptScore W2055099239C2776362946 @default.
• W2055099239 hasConceptScore W2055099239C2777025900 @default.
• W2055099239 hasConceptScore W2055099239C2778087573 @default.
• W2055099239 hasConceptScore W2055099239C2779438470 @default.
• W2055099239 hasConceptScore W2055099239C2780210213 @default.
• W2055099239 hasConceptScore W2055099239C2780394083 @default.
• W2055099239 hasConceptScore W2055099239C2909325608 @default.
• W2055099239 hasConceptScore W2055099239C502942594 @default.

• next